Viatris should receive a pan-European marketing authorization for its Kixelle (insulin aspart) biosimilar rival to NovoRapid, the Committee for Medicinal Products for Human Use within the European Medicines Agency has recommended in a positive opinion.
The European Commission typically acts on the CHMP’s